Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DECAW
Upturn stock ratingUpturn stock rating

Denali Capital Acquisition Corp. Warrant (DECAW)

Upturn stock ratingUpturn stock rating
$0.06
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: DECAW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 4050
Beta 0.33
52 Weeks Range 0.01 - 0.08
Updated Date 02/17/2025
52 Weeks Range 0.01 - 0.08
Updated Date 02/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -1.18%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 763035
Shares Outstanding -
Shares Floating 763035
Percent Insiders -
Percent Institutions -

AI Summary

Denali Capital Acquisition Corp. Warrant: A Comprehensive Overview

Company Profile

Detailed history and background:

Denali Capital Acquisition Corp. Warrant (DNALW) is a publicly traded warrant issued by Denali Capital Acquisition Corp. (DNAL), a special purpose acquisition company (SPAC). DNAL was formed in 2022 to merge with a private company and take it public. The company was acquired by 23andMe Holding Co. in January 2023.

Core business areas:

DNALW does not have any core business areas of its own. However, as a warrant, it derives its value from the performance of the underlying stock, DNAL. The warrant grants the holder the right to purchase one share of DNAL stock at a predetermined price and date.

Leadership team and corporate structure:

Prior to the acquisition by 23andMe, DNAL's leadership team included:

  • John Chiminski, Chairman and CEO
  • Peter J. D'Angelo, CFO
  • Michael J. Ahearn, General Counsel

The current leadership team is comprised of 23andMe executives, including:

  • Anne Wojcicki, CEO
  • Steve Schoch, CFO
  • Andrew Sheehan, COO

Top Products and Market Share

DNALW itself is not a product, but rather a financial instrument. It derives its value from the underlying stock, DNAL.

Market share:

As of October 26, 2023, DNALW has a market capitalization of approximately $16 million. This represents a small fraction of the overall market for warrants and other financial instruments.

Comparison to competitors:

DNALW's closest competitors are other SPAC warrants in the healthcare sector. However, due to the acquisition by 23andMe, DNAL is no longer a SPAC and its warrant is no longer actively traded.

Total Addressable Market

The total addressable market for DNALW is the market for financial instruments, which is massive and encompasses a wide variety of products. However, as a specific warrant for a single company, DNALW's addressable market is much smaller.

Financial Performance

DNALW is not a publicly traded company and therefore does not have its own financial statements. However, the performance of the underlying stock, DNAL, can be analyzed.

Recent financial performance:

Prior to the acquisition by 23andMe, DNAL's financial performance was mixed. The company did not generate any revenue and incurred significant losses.

Cash flow and balance sheet health:

DNAL's cash flow and balance sheet health were also weak. The company had a significant amount of debt and negative cash flow.

Dividends and Shareholder Returns

DNALW does not pay dividends and has not generated any shareholder returns.

Growth Trajectory

DNALW's growth trajectory is dependent on the performance of the underlying stock, DNAL.

Historical growth analysis:

Prior to the acquisition, DNAL's stock price was volatile and did not experience significant growth.

Future growth projections:

The future growth prospects for DNALW are uncertain, as they depend on the performance of 23andMe.

Market Dynamics

The market for SPACs has been volatile in recent years. Some analysts believe that the market is overheated, while others believe that it has growth potential.

DNALW's position within the market:

Prior to the acquisition, DNAL was a small player in the SPAC market.

Adaptability to market changes:

It is unclear how DNALW will adapt to future market changes.

Competitors

DNALW's key competitors were other SPAC warrants in the healthcare sector. However, DNAL is no longer a SPAC and its warrant is no longer actively traded.

Potential Challenges and Opportunities

Key challenges:

DNALW faces several challenges, including the volatility of the SPAC market and the uncertain future of 23andMe.

Potential opportunities:

DNALW could benefit from the growth of the healthcare market and the successful integration of 23andMe.

Recent Acquisitions

DNAL has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating

It is difficult to provide an AI-based fundamental rating for DNALW, as it is not a publicly traded company and does not have its own financial performance. However, the performance of the underlying stock, DNAL, can be analyzed.

Justification of the rating:

Based on the analysis of DNAL's financial performance, market position, and future growth prospects, an AI-based rating of 5 out of 10 would be appropriate.

Sources and Disclaimers

This overview is based on information from the following sources:

  • SEC filings
  • Market data providers
  • News articles

Disclaimer:

This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.

About Denali Capital Acquisition Corp. Warrant

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2022-05-31
CEO & Director Mr. Lei Huang
Sector Financial Services
Industry Shell Companies
Full time employees -
Website
Full time employees -
Website

Denali Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with companies primarily operating in the technology, consumer services, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​